The vector of anti-Kappa light chain chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human Kappa light chain. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-Kappa light chain antibody linked to CD3ζ and 4-1BB (CD137) signaling domains. And the vector product was designed for the treatment of non-Hodgkin's lymphoma.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE